Assyro AI

Orange Book product · Brand (NDA)

LAZCLUZE

LAZERTINIB MESYLATE

Brand (NDA)NDA 219008RX JANSSEN BIOTECH

At a glance

Aug 19, 2024

Approved

Brand (NDA)

Application

Not listed

TE code

8

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Aug 19, 2024

    1 yr 10 mo ago

  2. Today

  3. Exclusivity ends · NCE

    New chemical entity exclusivity (5 years)

    Aug 19, 2029

    in 3 yr 3 mo

  4. Patent 9593098 expires

    Listed drug substance patent expiration.

    Oct 13, 2035

    in 9 yr 5 mo

  5. Patent 11453656 expires

    Listed drug substance patent expiration.

    Apr 18, 2038

    in 12 yr

  6. Patent 11981659 expires

    Listed method-of-use patent (U-3985) expiration.

    Apr 18, 2038

    in 12 yr

  7. Patent 12318390 expires

    Listed drug product patent expiration.

    Apr 18, 2038

    in 12 yr

  8. Patent 12599606 expires

    Listed method-of-use patent (U-4512) expiration.

    May 14, 2040

    in 14 yr 1 mo

  9. Patent 11879013 expires

    Listed method-of-use patent (U-3985) expiration.

    May 21, 2040

    in 14 yr 2 mo

  10. Patent 12138351 expires

    Listed drug product patent expiration.

    Apr 13, 2041

    in 15 yr

  11. Patent 11850248 expires

    Listed method-of-use patent (U-3985) expiration.

    Aug 01, 2041

    in 15 yr 4 mo

Pharmaceutical detail

Active ingredient

LAZERTINIB MESYLATE

Strength

EQ 80MG BASE

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 219008

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

  • NCENew chemical entity exclusivity (5 years)

    Aug 19, 2029

    in 3 yr 3 mo

Listed patents (8)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
9593098Oct 13, 2035in 9 yr 5 mo
SubstanceProductU-3985
11453656Apr 18, 2038in 12 yr
SubstanceProduct
11981659Apr 18, 2038in 12 yr
U-3985
12318390Apr 18, 2038in 12 yr
Product
12599606May 14, 2040in 14 yr 1 mo
U-4512
11879013May 21, 2040in 14 yr 2 mo
U-3985
12138351Apr 13, 2041in 15 yr
Product
11850248Aug 01, 2041in 15 yr 4 mo
U-3985
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.